A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas

Trial Profile

A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Carboplatin
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Acronyms NABNEC
  • Most Recent Events

    • 20 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Nov 2018.
    • 28 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 18 May 2015 Status changed from not yet recruiting to recruiting, according to to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top